C

Cartography Biosciences

Develops precision immunotherapies targeting antigens

Principal Scientist / Associate Director - Developability & Protein Sciences

Translational Research & Bench BiologyUpdated on Nov 14
Full-timeSouth San Francisco, CA, USA$175k - $215k /yr

About the Job

Requirements

  • A PhD in protein science, biochemistry, biophysics, chemical or biological engineering, or a related discipline with 5+ years of biopharmaceutical industry experience for Principal Scientist or 8+ years for Associate Director; alternatively, an MS with commensurate additional directly relevant experience.
  • Hands-on experience with bispecific or multispecific antibodies, including analysis of product-related species.
  • Hands-on expertise with biophysical and developability methods, including DSF or DSC, analytical SEC, IEX, HIC, CE-SDS, intact mass, self-association assays such as AC-SINS, and polyspecificity assays such as BVP ELISA or PSR.
  • Developability triage experience in a research or discovery setting, translating biophysical data into candidate-selection decisions.
  • Experience with mammalian transient expression and multi-step antibody purification on FPLC systems such as AKTA or equivalent, including Protein A capture and polishing by IEX, HIC, or mixed-mode chromatography.
  • Experience serving as the protein sciences or developability expert on cross-functional therapeutic project teams, including presenting developability data that shaped a candidate-selection or advancement decision.
  • Ability to lead cross-functional teams without direct authority, including setting priorities, running team meetings, and driving decisions to closure.
  • Experience managing or mentoring scientists.
  • Hands-on experience writing code to analyze data or automate lab workflows, such as Python or R, including use of AI coding assistants such as Claude Code.

Responsibilities

  • Deliver developability and biophysical data for therapeutic programs as candidates advance from hit screening through lead optimization to development-candidate nomination.
  • Own the developability screening cascade, including thermal stability, aggregation, self-association, charge variants, hydrophobicity, polyspecificity, and molecular-integrity assessment.
  • Integrate in silico biophysical-property assessment, including sequence liabilities, surface-patch analysis, and aggregation propensity, with experimental data to prioritize and engineer candidates.
  • Characterize advanced leads and development candidates through stress and forced-degradation studies, PTM mapping such as peptide-mapping LC-MS, and early formulation development.
  • Help define and own developability criteria at each program decision gate and apply them consistently across programs.
  • Expand the throughput, robustness, and technical scope of protein analytics capabilities to support AI/ML-driven antibody engineering.
  • Oversee research-stage protein production from 1 mL to 10 L scale, in house and through external partners, as a service with clear intake, prioritization, turnaround, and quality acceptance of incoming material.
  • Optimize transient production of multi-chain bispecific and multispecific assemblies, including knob-into-hole heterodimers and VHH-containing trispecifics, including plasmid chain-ratio tuning to maximize correctly assembled product.
  • Direct purification strategies that resolve bispecific product-related species from correctly paired heterodimer, using Protein A capture with ion exchange, hydrophobic interaction, mixed-mode, and preparative size-exclusion polishing.
  • Scale plate-based expression and purification, in house and through external partners, to keep pace with screening throughput for the AI/ML-driven antibody-engineering platform.
  • Deliver low-endotoxin, high-monomer material meeting in vivo dosing specifications for mouse pharmacology and non-GLP nonhuman-primate studies.
  • Lead Protein Sciences work on cross-functional therapeutic program teams, bringing developability and manufacturability risk into design and advancement decisions and driving those decisions to closure.
  • As the portfolio grows, lead cross-functional program teams, aligning Antibody Engineering, Pharmacology, and Computational Biology around program goals, timelines, and gate decisions.
  • Communicate data, risks, and recommendations to program teams and leadership, and build alignment across functions on resulting decisions.
  • Manage, mentor, and develop scientists in protein purification and analytics, and set day-to-day practices and priorities for the function.
  • Build data capture, analysis, and automation into team workflows, working closely with team members who develop internal software and AI tools.

Desired Qualifications

  • Experience leading or co-leading a cross-functional therapeutic program team, or serving as deputy to a program lead.
  • Experience using in silico tools to predict antibody developability and biophysical properties.
  • Experience with PTM characterization by peptide-mapping LC-MS and stress and forced-degradation studies.
  • Formulation-development experience, particularly high-concentration (greater than 100 mg/mL) formulations for subcutaneous dosing.
  • Experience with liquid-handling automation and high-throughput purification and characterization.
  • Experience managing outsourced protein production or characterization.
  • Knowledge of T-cell-engaging antibody platforms and a background in oncology or immuno-oncology.
  • Experience building data pipelines, analysis tools, or agentic workflows with AI coding tools.

About the Company

Cartography Biosciences

Develops precision immunotherapies targeting antigens

Cartography Biosciences develops precision cancer immunotherapies. It identifies therapeutic targets by analyzing cancers through antigen expression instead of histology or genetic mutations, enabling therapies that specifically engage tumor cells while aiming to minimize harm to healthy tissue. The company designs and commercializes targeted immunotherapies and seeks druggable targets in cancers that are currently untreatable, striving for treatments that are as safe as they are effective and broadly applicable across tumor cells within a patient. In short, its goal is to deliver precise, safe, and potent cancer treatments by pairing a unique target-identification approach with immunotherapy platforms, and to bring these therapies to healthcare providers and patients through commercialization.

Company size
51-200
Company stage
Series B
Total funding
$124M
Headquarters
Foster City, CA
Founded
2020

Recently Posted Jobs

Explore more opportunities at Cartography Biosciences

See more jobs